ClinicalTrials.gg
CompletedNCT06035354Updated Mar 5, 2025

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

A Phase 1/2 interventional study of AK120 and AK120 in Atopic Dermatitis, sponsored by Akeso. Completed at 39 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Nov 2021, registered Jun 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
427
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
39th of 190
427 · median 164
Started
2021
with 12 others
Phase 1/2
15 of 206
5 open now
Registered
71st of 206
by date
Lead sponsor
6 of 206
Akeso

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 39th largest by enrollment of the 190 interventional ones that give a count, is one of 13 that started in 2021, is one of 15 in phase 1/2, and was the 71st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multicenter phase Ib/II clinical study to evaluate the safety, pharmacokinetics and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multicenter phase Ib/II clinical study to evaluate the safety, pharmacokinetics and efficacy of AK120 in subjects with moderate to severe atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female with age 18 - 75 years (inclusive).
  2. Atopic dermatitis (AD) diagnosed at least half an year before screening.
  3. Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline.
  4. Subjects with a history of an inadequate response or medically inappropriate use of topical drug treatment within 6 months.

Exclusion criteria

Exclusion Criteria:

  1. Suffering from other inflammatory diseases that may affect efficacy outcomes (such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease, overlap syndrome, etc.).
  2. History of exposure to active TB, and/or history or current evidence of TB infection.
  3. Positive serology results at Screening for , or .
  4. Any history of vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC) within 6 months before the baseline visit.
  5. History of clinical parasite infection, recent or planned travel to an area with endemic parasite infection within 6 months before the Screening visit
  6. Any medical or psychiatric condition, laboratory, or parameter which, in the opinion of the Investigator or the Sponsor's medical monitor, would place the subject at risk, interfere with participation in the study, or interfere with the interpretation of study results.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
427 participants (actual)

Study arms

  • Experimental
    AK120 150 mg in phase Ib

    subcutaneous injection once a week for 4 weeks.

    Drug: AK120

  • Experimental
    AK120 300mg in phase Ib

    subcutaneous injection once a week for 4 weeks.

    Drug: AK120

  • Placebo comparator
    Placebo Comparator: Placebo in phase Ib

    subcutaneous injection once a week for 4 weeks.

    Drug: Placebo

  • Experimental
    AK120 150mg in phase II

    subcutaneous injection every 2 weeks for 50 weeks.

    Drug: AK120

  • Experimental
    AK120 300mg in phase II

    subcutaneous injection every 2 weeks for 50 weeks.

    Drug: AK120

  • Experimental
    AK120 450mg in phase II

    subcutaneous injection every 2 weeks for 50 weeks.

    Drug: AK120

  • Placebo comparator
    Placebo Comparator: Placebo in phase II

    subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 4 and Regimen 5, subcutaneous injection at week 16, after primary endpoint evaluation.

    Drug: Placebo

  • Experimental
    AK120 150mg in phase II extension

    subcutaneous injection every 2 weeks for 14 weeks.

    Drug: AK120

  • Experimental
    AK120 300mg in phase II extension

    subcutaneous injection every 2 weeks for 14 weeks.

    Drug: AK120

  • Experimental
    AK120 450mg in phase II extension

    subcutaneous injection every 2 weeks for 14 weeks.

    Drug: AK120

Interventions

  • DrugAK120

    subcutaneous injection once a week

  • DrugAK120

    subcutaneous injection once a week

  • DrugPlacebo

    subcutaneous injection once a week.

  • DrugAK120

    subcutaneous injection every 2 weeks.

  • DrugAK120

    subcutaneous injection every 2 weeks.

  • DrugAK120

    subcutaneous injection every 2 weeks.

  • DrugPlacebo

    subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.

  • DrugAK120

    subcutaneous injection every 2 weeks

  • DrugAK120

    subcutaneous injection every 2 weeks.

  • DrugAK120

    subcutaneous injection every 2 weeks.

06

What researchers measure

Primary outcomes

  1. Phase Ib

    Incidence of treatment emergent AE . An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Baseline to week 12

  2. Phase Ib

    T1/2 of AK120. Assessment of half-life(t1/2) of AK120.

    Time frame: Baseline to week 12

  3. Phase Ib

    AUC of AK120. Assessment of Area under the curve(AUC) of AK120

    Time frame: Baseline to week 12

  4. Phase Ib

    Cmax of AK120. Assessment of Peak concentration(Cmax) of AK120

    Time frame: Baseline to week 12

  5. Phase Ib

    Tmax of AK120. Assessment of Time to peak(Tmax) of AK120

    Time frame: Baseline to week 12

  6. Phase II

    Percentage of subjects who achieved (Eczema Area and Severity Index)EASI-75

    Time frame: at week 16

  7. Phase II Extension Study

    Incidence of treatment emergent AE . An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Baseline to week 24

Secondary outcomes

  1. Phase Ib

    Percentage of subjects with detectable anti AK120 antibodies (ADA).

    Time frame: Baseline to week 12

  2. Phase Ib

    Percentage of subjects who achieved 0/1 in the Investigator's Global Assessment (IGA)(on a 6-point scale) . Lower score of IGA mean better outcome, higher score mean worse outcome

    Time frame: Baseline to week 12

  3. Phase II

    Percentage of subjects who achieved EASI-50 (≥50% improvement from baseline) /EASI-75 (≥75% improvement from baseline) response at each visit. Higher score mean better outcome, lower score mean worse outcome

    Time frame: Baseline to week 58

  4. Phase II

    Percentage change in EASI scores from baseline at each visit. Higher score mean better outcome, lower score mean worse outcome

    Time frame: Baseline to week 58

  5. Phase II Extension Study

    Percentage of subjects who achieved EASI-50 (≥50% improvement from baseline) /EASI-75 (≥75% improvement from baseline) response at each visit. Higher score mean better outcome, lower score mean worse outcome

    Time frame: Baseline to week 24

  6. Phase II Extension Study

    Percentage change in EASI scores from baseline at each visit. Higher score mean better outcome, lower score mean worse outcome

    Time frame: Baseline to week 24

07

Study locations

39 sites
  • AkesoBio Investigative Site 2037, The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • AkesoBio Investigative Site 2036, The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui, China
  • AkesoBio Investigative Site 1001, Peking University People's Hospital
    Beijing, Beijing, China
  • AkesoBio Investigative Site 2044, Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing, China
  • AkesoBio Investigative Site 2023, Xinqiao Hospital Medical University
    Chongqing, Chongqing, China
  • AkesoBio Investigative Site 2024, Chongqing Three Gorges Medical College
    Chongqing, Chongqing, China
  • AkesoBio Investigative Site 2040, Chongqing Traditional Chinese Medicine Hospital
    Chongqing, Chongqing, China
  • AkesoBio Investigative Site 2052, The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • AkesoBio Investigative Site 2038, The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • AkesoBio Investigative Site 2022, Dongguan People's Hospital
    Dongguan, Guangdong, China
  • AkesoBio Investigative Site 1002, Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
  • AkesoBio Investigative Site 2003, Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • AkesoBio Investigative Site 2049, The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou, China
  • AkesoBio Investigative Site 2004, The First Affiliated Hospital of Hainan Medical University
    Haikou, Hainan, China
  • AkesoBio Investigative Site 2001, Affiliated Hospital of Chengde medical university
    Chengde, Hebei, China
  • AkesoBio Investigative Site 2010, Nanyang First People's Hospital National Third Class A Hospital
    Nanyang, Henan, China
  • AkesoBio Investigative Site 2051, Jingzhou Central Hospital
    Jingzhou, Hubei, China
  • AkesoBio Investigative Site 1005, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • AkesoBio Investigative Site 2046, The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • AkesoBio Investigative Site 2008, The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia, China
  • AkesoBio Investigative Site 2048, The First People's Hospital of Changzhou
    Changzhou, Jiangsu, China
  • AkesoBio Investigative Site 2050, Wuxi Second People's Hospital
    Wuxi, Jiangsu, China
  • AkesoBio Investigative Site 2025, Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu, China
  • AkesoBio Investigative Site 2032, The First Affiliated Hospital of Gannan Medical College
    Ganzhou, Jiangxi, China
  • AkesoBio Investigative Site 2011, Northeast International Hospital
    Shenyang, Liaoning, China
  • AkesoBio Investigative Site 2039, Shandong Provincial Dermatology Hospital
    Jinan, Shandong, China
  • AkesoBio Investigative Site 2041, Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • AkesoBio Investigative Site 1003, Shanghai Skin Disease Hospital
    Shanghai, Shanghai, China
  • AkesoBio Investigative Site 2027, Medical School of Yanan University
    Xianyang, Shanxi, China
  • AkesoBio Investigative Site 2029, West China Hospital,Sichuan University
    Chengdu, Sichuan, China
  • AkesoBio Investigative Site 2034, Chengdu Second People's Hospital
    Chengdu, Sichuan, China
  • AkesoBio Investigative Site 2013, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin, China
  • AkesoBio Investigative Site 2019, Tianjin Medical University General Hospital
    Tianjin, Tianjin, China
  • AkesoBio Investigative Site 2043, First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • AkesoBio Investigative Site 1004, Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • AkesoBio Investigative Site 2006,Affiliated Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
  • AkesoBio Investigative Site 2007, Hangzhou Third People's Hospital
    Hangzhou, Zhejiang, China
  • AkesoBio Investigative Site 2035, The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • AkesoBio Investigative Site 2009, The First Hospital of Jiaxing
    Jiaxing, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jun 2024, 31 months.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 31 months is above that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2023
First posted
Sep 13, 2023
StartActual
Nov 3, 2021
Primary completionActual
Jun 21, 2024
CompletionActual
Jun 21, 2024
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06035354
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Nov 3, 2021
Primary completion
Jun 21, 2024
Completion
Jun 21, 2024
Last update
Mar 5, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK120

Start the discussion